Compare ABCL & WRBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABCL | WRBY |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | 2020 | 2021 |
| Metric | ABCL | WRBY |
|---|---|---|
| Price | $12.61 | $23.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $8.40 | ★ $27.10 |
| AVG Volume (30 Days) | ★ 4.4M | 2.4M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.91 | ★ 105.88 |
| EPS | N/A | ★ 0.06 |
| Revenue | $75,128,000.00 | ★ $871,905,000.00 |
| Revenue This Year | N/A | $14.48 |
| Revenue Next Year | $21.85 | $16.41 |
| P/E Ratio | ★ N/A | $387.50 |
| Revenue Growth | ★ 160.56 | 13.04 |
| 52 Week Low | $2.75 | $14.96 |
| 52 Week High | $13.18 | $31.00 |
| Indicator | ABCL | WRBY |
|---|---|---|
| Relative Strength Index (RSI) | 65.97 | 42.76 |
| Support Level | $10.38 | $21.13 |
| Resistance Level | N/A | $30.60 |
| Average True Range (ATR) | 0.61 | 1.23 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 79.02 | 27.08 |
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.